Articles By Cyndi Root

81. Drug Shortages: Actavis, Janssen, Teva, Sandoz, And More — 10/2/14 10/6/2014

    The Food and Drug Administration (FDA) has published its new and updated list of Drug Shortages through 10/2/14. The federal agency publicizes recalls on its website as press releases are not issued for all shortages. View the recalls by New and Updated.

82. Baxter Forms Boston R&D Center For New Spin-Off, Baxalta 10/3/2014

    Baxter International intends to form a new R&D center near Boston, MA for Baxalta, the company formed when Baxter splits the company into two entities in 2015. The move, announced in a press release, will locate the development unit in Cambridge, a biotech hub, to support Baxalta’s focus on biopharmaceuticals. Scientists at the facility will focus on immunology and hematology using gene therapy and biosimilar technology.

83. Daiichi Sankyo Acquires Ambit Biosciences, Quizartinib For AML 10/2/2014

    Daiichi Sankyo has acquired Ambit Biosciences in a definitive merger agreement. The move, announced in a press release, also transfers Ambit Bioscience’s quizartinib — currently in Phase 3 clinical trials for patients with acute myeloid leukemia (AML) — into Daiichi Sankyo’s oncology pipeline. Michael A. Martino, President and CEO of Ambit Biosciences, said, “Daiichi Sankyo is the ideal organization to take quizartinib to the next stage of development, and ultimately, to achieve our goal of making it available as quickly as possible to help as many AML patients as possible.”

84. Boehringer Ingelheim Expands Respimat Production For Respiratory Medications 10/2/2014

    Boehringer Ingelheim is expanding its Dortmund, Germany site to increase Respimat inhaler production capacity for its respiratory medications. The move, announced in a press release, will increase production to 44 million units per year for the device that administers Combivent, Spiriva, and Striverdi for chronic obstructive pulmonary disease (COPD) drugs. Dr. Wolfgang Baiker, of Boehringer Ingelheim’s Board of Managing Directors, said, “The Respimat inhaler will also, in the future, be the inhalation device for applying our respiratory medications.”

85. Weekly FDA Enforcement Report For Drugs 9/24/14 9/26/2014

    The Food and Drug Administration (FDA) has released its Drug product Enforcement Report for September 24, 2014. The agency publicizes recalls in its weekly report as press releases are not issued for all recalls. Manufacturers issue recalls voluntarily or the FDA initiates the action. View the recalls by Classification.

86. Takeda, BioMotiv Partner On Immunology, Inflammation, Cardio-Metabolic Diseases 9/26/2014

    Takeda and BioMotiv have announced a partnership to develop therapeutic candidates in the areas of immunology, inflammation, and cardio-metabolic diseases. The collaboration, and Takeda’s financial investment in BioMotiv, was announced in a joint press release.

87. Baxter Licenses Merrimack's Nanoliposomal Irinotecan Injection For Pancreatic Cancer 9/26/2014

    Baxter International has licensed Merrimack Pharmaceuticals’ MM-398 (nanoliposomal irinotecan injection) for pancreatic cancer. Baxter announced the exclusive license and collaboration agreement in a press release, stating that it acquired worldwide rights, excluding the U.S. and Taiwan.

88. Merck KGaA Acquires Sigma-Aldrich, Extends Reach To N. America, Asia 9/24/2014

    Merck has acquired Sigma-Aldrich for $17 billion, extending its product line and global reach to North America and Asia.

89. Hospira Invests In Mulgrave Facility, Calls For Pharma Manufacturing Taskforce 9/23/2014

    Hospira is investing $15 million in its Mulgrave, Australia manufacturing facility. The move was announced in a press release and commemorated by a visit from Ian Macfarlane, Industry Minister.

90. Covance, Frenova Partner On Kidney, Renal Disease Treatments 9/19/2014

    Covance and Frenova Renal Research have established a new research collaboration to find treatments for patients with chronic kidney disease (CKD) and end stage renal disease (ESRD).